Combining azacitidine with venetoclax (Venclexta) significantly increased event-free survival (EFS) vs intensive induction ...

Transitioning the dose of axatilimab (Niktimvo) from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks appeared feasible in ...

The combination of carfilzomib (Kyprolis) plus lenalidomide (Revlimid) and dexamethasone (KRd) improved progression-free ...

Blinatumomab/ponatinib increased efficacy and response rates were improved in patients with Philadelphia-positive acute lymphoblastic leukemia.

Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...

The addition of epcoritamab to R2 significantly reduced the risk of death or disease progression in patients with relapsed/refractory follicular lymphoma.

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

The FDA has approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the treatment of adult patients with relapsed or ...

From clinical trials, to psychosocial needs, to care transitioning, adolescent and young adult patients with cancer face ...

The FDA has approved pirtobrutinib (Jaypirca) treatment for adults with relapsed/refractory chronic lymphocytic leukemia or ...

A patient acuity model drove efficient and safe staffing through data from a natural language processing model informed by ...

After a radical hysterectomy and pelvic lymphadenectomy for early-stage cervical cancer, patients often face decisions about ...